Announcing a new publication for BIO Integration journal. In this review article the authors Zeling Guo, Shanping Jiang, Zilun Li and Sifan Chen from Sun Yat-Sen University, Guangzhou, China review how metabolic syndrome “interacts” with COVID-19.
Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide and has exerted a great influence on public health and society. Metabolic disturbance involving various organs has been found in COVID-19 patients, including diabetes, fatty liver and acute kidney injury (AKI). In turn, pre-existing metabolic syndromes could exacerbate the effects of COVID-19. In this review, the authors focus on the close interaction between COVID-19 and metabolic syndrome, as well as the potential of repurposing metabolic-related drugs and the importance of treating metabolic diseases in COVID-19 patients.
Article reference: Zeling Guo, Shanping Jiang, Zilun Li and Sifan Chen, Metabolic Syndrome “Interacts” With COVID-19, BIO Integration, 2021, https://doi.org/10.15212/bioi-2020-0035
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
BIOI is now open for submissions; articles can be submitted online at:
Please visit www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (www.bio-integration.org).
There are no author submission or article processing fees.